Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04592666
Other study ID # ALMO-PEME-CAR-01
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 9, 2020
Est. completion date June 30, 2022

Study information

Verified date October 2020
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 226
Est. completion date June 30, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Between 18 and 75 years old (including 18 and 75 years old); 2. Histologically or cytologically confirmed locally advanced or metastatic (STAGE IIIB-IV) NSCLC does not accept simple sputum smear-based diagnosis; 3. Previous genetic tests confirmed egFR-sensitive mutations, and received one or two generations of EGFR TKI treatment. After drug resistance, it was confirmed to be positive for EGFR T790M mutation by biopsy or free DNA test. 4. The patient has at least one tumor lesion that has not received local treatment such as radiation or biopsy in the screening stage, and can be accurately measured at baseline, with the longest diameter = 10mm at baseline (short diameter = 15mm if lymph nodes are involved).The measurement method chosen is suitable for accurate repeated measurements and can be computed tomography (CT) or magnetic resonance imaging (MRI).If there is only one measurable lesion and no previous local treatment such as irradiation, it can be accepted as the target lesion for baseline evaluation of tumor lesions after at least 14 days of diagnostic biopsy. 5. Life expectancy is at least 3 months; 6. ECOG score: 0-1, with no significant clinical deterioration in the past 2 weeks; 7. The main organs function normally, that is, they meet the following standards: blood routine examination standards must be in accordance with no blood transfusion and adjuvant therapies (14 days) : A. Hemoglobin (HB) =90 g/L; B. Absolute value of neutrophils (ANC) =1.5×109/L; C. Platelet (PLT) =100×109/L; D. Total bilirubin (TBIL) <1.5 times the upper limit of normal value (ULN); E. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5×ULN, if accompanied by liver metastasis, ALT and AST< 5×ULN; F. Serum Cr<1.25×ULN or endogenous creatinine clearance rate (CCr) > 45 ml/min (Cockcroft-Gault formula); Exclusion Criteria: 1. Patients who have received three generations of EGFR-TKI treatment; 2. Patients with mixed small cell lung cancer components; 3. Patients with advanced or metastatic disease who have received palliative chemotherapy, or patients with tumor recurrence and metastasis within 6 months after radical surgery with adjuvant chemotherapy; 4. Patients with symptomatic brain metastasis, meningeal metastasis or spinal cord compression; 5. Patients with previous diagnosis of interstitial pneumonia; 6. Uncontrolled hypertension (systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg, despite the best medication); 7. with severe cardiovascular disease: ? magnitude of myocardial ischemia and myocardial infarction, poor control of cardiac arrhythmias (including QTc interphase male 450, female 470 ms or ms or higher);According to NYHA standard, ? ~ ? cardiac insufficiency, or heart colour to exceed revealed left ventricular ejection fraction (LVEF) < 50%; 8. abnormal coagulation function (INR >1.5 or prothrombin time (PT) > ULN+4 seconds or APTT > 1.5uln), bleeding tendency or receiving thrombolytic or anticoagulant therapy; Note: Under the condition that the international standard ratio of prothrombin time (INR) =1.5, low-dose heparin (daily dosage for adults ranges from 66,000 to 12,000 U) or low-dose aspirin (daily dosage =100 mg) is allowed for preventive purposes. 9. Peripheral neuropathy =CTCAE 2 is present, except for trauma; 10. Respiratory syndrome (=CTCAE level 2 dyspnea), uncontrolled serous cavity effusion (including pleural effusion, ascites and pericardial effusion); 11. A wound or fracture that has not been healed for a long time; 12. Severe infections requiring systemic antibiotics; 13. Decompensated diabetes mellitus or other contraindications of high-dose glucocorticoid therapy; 14. Active hepatitis C and/or hepatitis B infection (hepatitis B: HBsAg positive with HBV DNA=500IU/mL;Hepatitis C: HCV RNA positive); 15. Factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction; 16. Had major surgery or severe traumatic injury, fracture or ulcer within the first 4 weeks; 17. Any contraindications for platinum (carboplatin) and cytotoxic drug (Pemetrexed) treatment; 18. Other conditions deemed inappropriate by the researcher for inclusion in the study.

Study Design


Intervention

Drug:
Almonertinib
the standard therapy of single agent almonertinib
Pemetrexed
standard dose
Carboplatin
AUC=5

Locations

Country Name City State
China Cancer hospital Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFS progression free survival from the first cycle of treatment (day one) to two month after the last cycle (each cycle is 21 days)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06071013 - Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients Phase 1/Phase 2
Recruiting NCT05598528 - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT04042558 - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Phase 2
Not yet recruiting NCT06018688 - Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. Phase 2
Active, not recruiting NCT04013542 - Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Phase 1
Recruiting NCT05517083 - Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer N/A
Active, not recruiting NCT03065387 - Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Phase 1
Completed NCT03653546 - First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases Phase 2/Phase 3
Recruiting NCT03720873 - EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC Phase 2
Active, not recruiting NCT02954523 - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Active, not recruiting NCT03732352 - 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma Phase 2
Completed NCT04552613 - Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients N/A
Completed NCT03755102 - A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. Early Phase 1
Recruiting NCT02338011 - Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases) Phase 2/Phase 3
Recruiting NCT04085315 - Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Phase 1
Not yet recruiting NCT06117644 - The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Recruiting NCT03396185 - Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer Phase 2
Recruiting NCT03042221 - Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Not yet recruiting NCT06222489 - Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT Phase 2